Biotoscana Investments SA (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced its financial results for 2018 on Friday.

The company reported an increase in net revenue for 2018 of 10% in constant currency, positively impacted by its Dosa drug, marking BRL821m.

The firm posted net income at BRL63m in 2018 compared with BRL17m in 2017.

Gross profit increased by 12% vs 2017, in constant currency.

Gross margin of 51% (including hyperinflation adjustments) vs 54% in 2017.

OPEX are in line with 34% of net revenues in 2018.

(1USD=4BRL)